Identification of fluocinolone acetonide to prevent paclitaxel‐induced peripheral neuropathy. Issue 3 (September 2016)

• Record Type: Journal Article
• Authors: Cetinkaya‐Fisgin, Aysel; Joo, Min Geol; Ping, Xiang; Thakor, Nitish V.; Ozturk, Cengizhan; Hoke, Ahmet; Yang, In Hong
• Is Part Of: Journal of the peripheral nervous system. Volume 21:Issue 3(2016)
• Page Start: 128
• Page End: 133
• Publication Date: 2016-09
• Subjects: chemotherapy‐induced peripheral neuropathy -- fluocinolone acetonide -- paclitaxel -- phenotypic drug screening; Nervous system -- Periodicals; Nerves, Peripheral -- Diseases -- Periodicals; Peripheral Nervous System Diseases -- Periodicals; Peripheral Nervous System -- Periodicals; 612.81
• DOI: 10.1111/jns.12172
• Languages: English
• ISSNs: 1085-9489

Abstract

Abstract: Paclitaxel (PTX) is among the most commonly used cancer drugs that cause chemotherapy‐induced peripheral neuropathy (CIPN), a debilitating and serious dose‐limiting side effect. Currently, no drugs exist to prevent CIPN, and symptomatic therapy is often ineffective. In order to identify therapeutic candidates to prevent axonal degeneration induced by PTX, we carried out a phenotypic drug screening using primary rodent dorsal root ganglion sensory neurons. We identified fluocinolone acetonide as a neuroprotective compound and verified it through secondary screens. Furthermore, we showed its efficacy in a mouse model of PTX‐induced peripheral neuropathy and confirmed with four different cancer cell lines that fluocinolone acetonide does not interfere with PTX's antitumor activity. Our study identifies fluocinolone acetonide as a potential therapy to prevent CIPN caused by PTX.